Altimmune (ALT) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed Altimmune (ALT) over the past year, losing 5.8% versus a loss of 33.8%. Over five years, DRUG leads with a +40.0% price change compared with -78.4% for ALT. Bright Minds Biosciences is the larger company by market cap ($540.3 million vs $507.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | DRUG |
|---|---|---|
| Share price | $2.61 | $54.78 |
| Market cap | $507.69M | $540.30M |
| 1-day change | +0.38% | +5.34% |
| YTD return | -27.98% | -33.37% |
| 1-year return | -33.84% | -5.80% |
| 5-year return | -78.35% | +39.97% |
| EPS (TTM) | $-0.76 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $123.75 |
| 52-week low | $2.55 | $47.23 |
| Distance from 52-week high | -59.47% | -55.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +555.56% | +177.44% |
| Average volume | 4.21M | 159.01K |
| Shares outstanding | 194.52M | 9.86M |
| Employees | 57 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRUG has outperformed ALT by 28.0 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
ALT vs DRUG FAQ
Which is bigger, Altimmune or Bright Minds Biosciences?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $540.30M compared with $507.69M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or DRUG?
DRUG returned -5.80% over the past 12 months, compared with -33.84% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.